Molecular Mechanism Regulating Regeneration of Spinal Nerves Identified
|
By LabMedica International staff writers Posted on 29 Mar 2016 |

Image: A confocal micrograph of the lesion core following spinal cord injury. Nuclear EdU (red) shows the presence of newly differentiated cells which produce Schwann cell myelin (green). These peripheral-like Schwann cells remyelinate central axons in the injured spinal cord and are important for spontaneous repair and functional recovery after spinal cord injury (Photo courtesy of King\'s College London).
The protein neuregulin-1 was found to regulate the repair mechanism that attempts to restore lost myelin following spinal cord injury.
Following traumatic spinal cord injury, acute demyelination of spinal axons is followed by a period of spontaneous remyelination. However, this endogenous repair response is incomplete and may account for the chronic loss of function demonstrated by surviving axons. Spontaneous remyelination is largely mediated by Schwann cells, where demyelinated central axons, particularly in the dorsal columns, become associated with peripheral myelin. The molecular control mechanism, functional role, and origin of these central remyelinating Schwann cells are currently unknown.
The growth factor neuregulin-1 (Nrg1, encoded by the NRG1 gene) is a key signaling factor controlling myelination in the peripheral nervous system, via signaling through ErbB tyrosine kinase receptors. The neuregulins are a family of four structurally related proteins that are part of the EGF (epidermal growth factor) family of proteins, which have been shown to have diverse functions in the development of the nervous system.
Investigators at King's College London (United Kingdom) and the University of Oxford (United Kingdom) examined whether Nrg1 was required for Schwann cell-mediated remyelination of central dorsal column axons and whether removal of Nrg1 would influence the degree of spontaneous remyelination and functional recovery following spinal cord injury.
They reported in the March 17, 2016, online edition of the journal Brain that Nrg1 signaling mediated an endogenous regenerative event in which Schwann cells remyelinated denuded central axons after traumatic spinal cord injury and that Nrg1 was an important mediator of spontaneous functional repair after spinal cord injury. In mice lacking the NRG1 gene, spontaneous myelin repair was completely prevented and spinal nerve fibers remained demyelinated. Furthermore, mice without NRG1 showed worse outcomes after spinal cord injury compared to mice with the gene intact, particularly in walking, balance, and coordinated movements.
Senior author Dr. Elizabeth Bradbury, professor of regenerative medicine and neuroplasticity at King's College London, said, "Spinal cord injury could happen to anyone, at any time. In an instant your life could change and you could lose all feeling and function below the level of the injury. Existing treatments are largely ineffective, so there is a pressing need for new regenerative therapies to repair tissue damage and restore function after spinal cord injury."
"These new findings advance our understanding of the molecular mechanisms which may orchestrate the body's remarkable capacity for natural repair," said Dr. Bradbury.
"By enhancing this spontaneous response, we may be able to significantly improve spinal cord function after injury. Our research also has wider implications for other disorders of the central nervous system which share this demyelinating pathology, such as multiple sclerosis."
Related Links:
King's College London
University of Oxford
Following traumatic spinal cord injury, acute demyelination of spinal axons is followed by a period of spontaneous remyelination. However, this endogenous repair response is incomplete and may account for the chronic loss of function demonstrated by surviving axons. Spontaneous remyelination is largely mediated by Schwann cells, where demyelinated central axons, particularly in the dorsal columns, become associated with peripheral myelin. The molecular control mechanism, functional role, and origin of these central remyelinating Schwann cells are currently unknown.
The growth factor neuregulin-1 (Nrg1, encoded by the NRG1 gene) is a key signaling factor controlling myelination in the peripheral nervous system, via signaling through ErbB tyrosine kinase receptors. The neuregulins are a family of four structurally related proteins that are part of the EGF (epidermal growth factor) family of proteins, which have been shown to have diverse functions in the development of the nervous system.
Investigators at King's College London (United Kingdom) and the University of Oxford (United Kingdom) examined whether Nrg1 was required for Schwann cell-mediated remyelination of central dorsal column axons and whether removal of Nrg1 would influence the degree of spontaneous remyelination and functional recovery following spinal cord injury.
They reported in the March 17, 2016, online edition of the journal Brain that Nrg1 signaling mediated an endogenous regenerative event in which Schwann cells remyelinated denuded central axons after traumatic spinal cord injury and that Nrg1 was an important mediator of spontaneous functional repair after spinal cord injury. In mice lacking the NRG1 gene, spontaneous myelin repair was completely prevented and spinal nerve fibers remained demyelinated. Furthermore, mice without NRG1 showed worse outcomes after spinal cord injury compared to mice with the gene intact, particularly in walking, balance, and coordinated movements.
Senior author Dr. Elizabeth Bradbury, professor of regenerative medicine and neuroplasticity at King's College London, said, "Spinal cord injury could happen to anyone, at any time. In an instant your life could change and you could lose all feeling and function below the level of the injury. Existing treatments are largely ineffective, so there is a pressing need for new regenerative therapies to repair tissue damage and restore function after spinal cord injury."
"These new findings advance our understanding of the molecular mechanisms which may orchestrate the body's remarkable capacity for natural repair," said Dr. Bradbury.
"By enhancing this spontaneous response, we may be able to significantly improve spinal cord function after injury. Our research also has wider implications for other disorders of the central nervous system which share this demyelinating pathology, such as multiple sclerosis."
Related Links:
King's College London
University of Oxford
Latest BioResearch News
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more
Rapid Point-of-Care RT-PCR Test Differentiates Influenza A/B and SARS-CoV-2 in Minutes
Respiratory viruses such as influenza A/B and SARS‑CoV‑2 continue to burden urgent care and emergency settings, where rapid, reliable differentiation guides therapy and infection control.... Read moreHematology
view channel
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read more
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







